TrialCompass TCL
Back to results
Phase 2RecruitingPriority 3 · Moderate priorityNCT06519526

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is testing SHR-0302 and SHR-2554 for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 70 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

SHR-0302 (DRUG): SHR-0302 will be administered orally as tablets. | SHR-2554 (DRUG): SHR-2554 will be administered orally as tablets.

Drugs / treatments
SHR-0302, SHR-2554
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

NCT06519526

Phase: Phase 2 | Status: Recruiting | Priority: Medium

Plain-language summary

This Phase 2 trial is testing SHR-0302 and SHR-2554 for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 70 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

What's being tested

SHR-0302 (DRUG): SHR-0302 will be administered orally as tablets. | SHR-2554 (DRUG): SHR-2554 will be administered orally as tablets.

Drugs / treatments: SHR-0302, SHR-2554

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 25 patients

Primary endpoint: Incidence and severity of AEs and SAEs; Objective response rate (ORR)

Ages: 18 Years to 70 Years

Start date: 2024-08-12 | Est. completion: 2027-08-31

Locations

0 US sites · 1 total

Contact

Rong Tao, MD | rtao@shca.org.cn | 8621-64175590

Sponsor: Fudan University (OTHER)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06519526

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.